EAM Investors’s Nektar Therapeutics NKTR Stock Holding History

EAM Investors’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.6M	Buy	36,126 +23,154	+178%	+$1.32M	0.3%	151
2025 Q4	$548K	Sell	12,972 -65,237	-83%	-$3.65M	0.06%	255
2025 Q3	$4.4M	Buy	78,209 +54,053	+224%	+$1.79M	0.5%	89
2025 Q2	$624K	Buy	+24,156	New	+$271K	0.09%	199
2018 Q2	–	Sell	-4,270	Closed	-$6.81M	–	333
2018 Q1	$6.81M	Buy	4,270 +333	+8%	+$429K	1.13%	1
2017 Q4	$3.53M	Sell	3,937 -2,777	-41%	-$1.64M	0.63%	29
2017 Q3	$2.42M	Sell	6,714 -2,023	-23%	-$633K	0.32%	127
2017 Q2	$2.56M	Sell	8,737 -631	-7%	-$182K	0.42%	113
2017 Q1	$3.3M	Buy	+9,368	New	+$2.11M	0.52%	58

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

EAM Investors's NKTR Position: Q1 2026 in Review

EAM Investors increased its Nektar Therapeutics (NKTR) stake by 178% in Q1 2026, buying an estimated $1.32M and bringing the position to 36,126 shares worth $2.6M. The position accounts for 0.3% of the portfolio, ranked #151.

EAM Investors first reported a position in NKTR in Q1 2017 and has held it in 9 quarters since. The position peaked at $6.81M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

EAM Investors held 36,126 shares of Nektar Therapeutics worth $2.6M as of Q1 2026.
EAM Investors bought 23,154 Nektar Therapeutics shares in Q1 2026, an estimated $1.32M.
Nektar Therapeutics made up 0.3% of EAM Investors's portfolio in Q1 2026, its #151 holding.
EAM Investors first reported a position in Nektar Therapeutics in Q1 2017 and has held it in 9 quarters since.
EAM Investors's Nektar Therapeutics position peaked at $6.81M in Q1 2018.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.